Ergomed PLC (AIM:ERGO, ETR:2EM, FRA:2EM) said strong organic growth and the integration of acquired businesses drove strong results in the first half of the year.
Total revenue climbed 39% to £56mln with adjusted underlying earnings (EBITDA) up 33% to £12mln. Cash at the end of June was £24mln with no debt.
READ: Ergomed sees exceptional first half performance
Net new sales awards surged 51% and the order book of future contracted revenue jumped 50% to £227mln.
"The excellent financial results that Ergomed has reported in the first half of 2021 reflect continued strong organic growth and the successful integration of value-enhancing acquisitions with significant new business won in both the pharmacovigilance and CRO businesses,” said executive chairman Dr Miroslav Reljanović.
“Global demand for our services continues to strengthen and our confidence in the long-term growth of the company is underpinned by the buoyant markets in which we operate, our acquisition strategy, and the robust platform provided by our order book and balance sheet."